POMPANO BEACH, Fla., April 15, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (Nasdaq:DSKX), "DS Healthcare" or "the Company" a leading developer of personal care products has released financial results for the fourth quarter and full year for 2014.
Q4 2014 Highlights:
- Net revenues were $ 3,706,761 up 21% over Q4 2013
- Gross margins increase to 60.1% from 51.3% in Q4 2013
- Gross profits increase to $2,244,930 up 43% over Q4 2013
- Company reports net income of $227,662 compared to a loss of $(944,860) in Q4 2013
- Adjusted EBITDAS, a non-GAAP financial measure resulted in a net gain of $1,007,847 from a loss of $(399,789) in Q4 2013
"The turn to profitability that we've achieved during the fourth quarter further demonstrates our continued efforts to provide our shareholders with solid performance. We have greatly improved our efficiency and fulfillment cycle with the expectation to realize the benefits from these recent changes and initiatives on an on-going basis. We are confident these implementations will significantly drive our domestic and international revenues. Sales within our Mexican subsidiary continue to be robust and growing, posting a 54.7 increase in the fourth quarter of 2014 over the fourth quarter of 2013. As we continue to receive international regulatory approvals, we remain very optimistic for continued revenue growth in key market segments," stated DS Healthcare President and CEO Daniel Khesin.
Net revenues were $3,706,761 for the three months ended December 31, 2014, an increase of 21% over revenues of $3,058,626 in the year-earlier period. Revenue growth in the fourth quarter was driven by higher sales from the Company's Mexican subsidiary, increased revenue from international markets and a resumption of growth in our domestic sales.
Gross margin increased to 60.6% in the fourth quarter of 2014 from 51.3% in the same quarter of the prior year. This notable increase was a result of several factors including production efficiencies, strategic cost cutting efforts, increased sales of higher margin products and lower returns due to improved product quality. Gross profits were up 43% to $2,244,930 in the fourth quarter of 2014, as compared to $1,570,423 in the year-earlier period. Selling and marketing costs increased by 12% to $1,022,814 in the recent quarter from $913,951 in the same period last year. General and administrative costs decreased by 44.4% to $958,493, as compared to $1,723,995 in the same period of 2013. DS Healthcare reported net loss narrowed by 125% to a net income of $227,662 in the fourth quarter of 2014 compared to a net loss $(944,859) in the same period of 2013.
On an adjusted EBITDAS basis, a non-GAAP financial measure, the fourth quarter of 2014 resulted in a gain of $1,007,847 compared to a loss of $(399,789) in the year-earlier period.
For the twelve months ended December 31, 2014 net revenues were $13,414,265, a 1.7% decline from revenues of $13,561,661 for the twelve months ended December 31, 2013. Net revenues decreased primarily due to a decrease in US net revenue which was offset by increases in net revenues generated through our Mexican subsidiary which grew by 31.7% that were slightly offset due to a stronger dollar compared to the Mexican peso and impacted by shipments from the fourth quarter that have rolled into the first quarter in 2015. The decrease in US net revenue was the result of a weaker-than-expected first quarter 2014 caused by product backorders and other operational challenges, while revenues from international sales experienced delays in international product registrations and a stronger dollar compared to international currencies.
Gross margin increased to 60.6% in the full year of 2014 from 49.1% in the prior year, as a result of improved production efficiencies, cost cutting efforts including payroll, improved forecasting which has led to decreased manufacturing costs and reduced product returns by improving product quality. Gross profits were up 21% to $8,133,356 in for the twelve months of 2014, as compared to $6,708,618 in 2013. Selling and marketing costs increased by 9.4% to $4,099,419 in 2014 from $3,747,213 in 2013 General and administrative costs decreased by 11% to $5,299,779 in 2014 as compared to $5,964,570 in 2013. DS Healthcare's net loss decreased by 59% to $(1,312,159) or $(0.08) per share in 2014 from $(3,225,290) or $(0.25) per share in 2013.
As of December 31, 2014 the Company had cash and cash equivalents of $1,128,556 and working capital of $3,767,179. Total stockholders' equity on December 31, 2014 was $5,138,208.
On an adjusted EBITDAS basis, a non-GAAP financial measure, 2014 resulted in a loss of $(406,271) share compared to a loss of $(1,169,338) in 2013.
"The operational challenges we were faced with in early 2014 have successfully been addressed as we made considerable changes to nearly every department. This has been a pivotal year with our resources committed to creating a platform of efficacy in preparation for significant topline growth in the near future. The early outcome was demonstrated in Q3 and Q4, and while we continue to make progress on a daily basis, we believe that we can still improve upon the potential in gross margins, profitability and sales. Our products have proven to serve as a solution to a growing number of personal care needs, and by adequately servicing our customers the opportunities are endless," Khesin started. "With the pipeline of new products expected to launch in the first half of 2015 that leverage our development expertise and innovation, we are very optimistic with the outlook for this year and beyond," Khesin concluded.
Adjusted EBITDAS
We believe Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation ("Adjusted EBITDAS"), a non-GAAP financial measure, is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary for different companies for reasons unrelated to overall operating performance. We believe that:
- Adjusted EBITDAS provides investors and other users of our financial information consistency and comparability with our past financial performance, facilitates period-to-period comparisons of operations and facilitates comparisons with other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and
- Adjusted EBITDAS is useful because it excludes non-cash charges, such as depreciation and amortization, stock-based compensation and one-time charges, which the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and these expenses can vary significantly between periods
We use Adjusted EBITDAS in conjunction with traditional GAAP measures as part of our overall assessment of our performance, to evaluate the effectiveness of our business strategies and to communicate with our lenders, stockholders and board of directors concerning our financial performance.
Adjusted EBITDAS should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP. There are limitations to using non-GAAP financial measures, including that other companies may calculate these measures differently than we do. We compensate for the inherent limitations associated with using Adjusted EBITDAS through disclosure of these limitations, presentation of our financial statements in accordance with GAAP and reconciliation of Adjusted EBITDAS to the most directly comparable GAAP measure, specifically net loss.
The following provides a reconciliation of net loss to Adjusted EBITDAS
| For Years Ended | ||
| December 31, | ||
| (unaudited) | ||
| 2014 | 2013 | |
| GAAP Net Loss | $ (1,312,159) | $ (3,225,290) |
| Depreciation and amortization | 299,983 | 607,018 |
| Amortization of deferred issuance costs | -- | 75,891 |
| Interest Expense | 71,536 | 115,150 |
| Loss on sale of fixed asset | -- | 21,637 |
| Impairment of intangible assets | 51,736 | 88,910 |
| Bad debt allowance | (36,363) | 90,045 |
| Inventory obsolescence allowance | (162,463) | 49,720 |
| Stock issued for services | 681,459 | 717,981 |
| Loss on extinguishment of debt - shareholder | -- | 289,600 |
| Adjusted EBITDAS | $ (406,271) | $ (1,169,338) |
| Three Months Ended | ||
| December 31, | ||
| (unaudited) | ||
| 2014 | 2013 | |
| GAAP Net Income (loss) | $227,661 | $ (944,861) |
| Depreciation and amortization | 82,556 | 323,288 |
| Amortization of deferred issuance costs | -- | 27,983 |
| Interest | 12,660 | 30,262 |
| Loss on disposal of fixed asset | (7,305) | 16,511 |
| Impairment of intangible assets | 51,736 | 88,910 |
| Bad debt allowance | 23,940 | (229,711) |
| Inventory obsolescence allowance | 52,312 | 37,193 |
| Stock issued for services | 564,285 | 250,636 |
| Adjusted EBITDAS | $1,007,847 | $ (399,789) |
| DS Healthcare Group, Inc. (dba DS Laboratories) and Subsidiaries | ||
| Consolidated Balance Sheets | ||
| (unaudited) | ||
| December 31, | ||
| 2014 | 2013 | |
| ASSETS | ||
| Current Assets | ||
| Cash | $ 1,128,556 | $ 2,872,946 |
| Accounts receivable, net | 1,809,178 | 2,229,329 |
| Inventories, net | 3,984,528 | 2,702,579 |
| Prepaid expenses and other current assets | 278,714 | 289,885 |
| Total Current Assets | 7,200,976 | 8,094,739 |
| Furniture and Equipment, net | 206,406 | 206,958 |
| Intangible Assets, net | 1,101,373 | 1,346,389 |
| Other Assets | 88,247 | 66,506 |
| TOTAL ASSETS | $ 8,597,002 | $ 9,714,592 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $ 1,229,863 | $ 2,230,723 |
| Accrued expenses | 967,112 | 945,949 |
| Credit facility | 350,000 | 582,383 |
| Other current liabilities | 886,822 | 286,282 |
| Total Current Liabilities | 3,433,797 | 4,045,337 |
| Long Term Debt, net of current portion | 24,997 | 36,425 |
| TOTAL LIABILITIES | 3,458,794 | 4,081,762 |
| COMMITMENTS AND CONTINGENCIES | ||
| Shareholders' Equity | ||
| Preferred stock, $0.001 par value, 30 million shares authorized:0 shares issued and outstanding at December 31, 2014 and 2013 | — | — |
| Common stock, $0.001 par value, 300 million shares authorized: 16,202,268 and 15,843,005 shares issued and outstanding at December 31, 2014 and 2013, respectively | 16,202 | 15,843 |
| Additional paid-in-capital | 14,839,695 | 14,163,595 |
| Stock subscription | (2,500) | (194,500) |
| Accumulated deficit | (9,613,375) | (8,307,420) |
| Accumulated comprehensive income | (63,384) | (12,462) |
| Total Shareholders' Equity | 5,176,638 | 5,665,056 |
| Non-Controlling Interest | (38,430) | (32,226) |
| Total Shareholders' Equity | 5,138,208 | 5,632,830 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 8,597,002 | $ 9,714,592 |
| DS Healthcare Group, Inc. (dba DS Laboratories) and Subsidiaries | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| (unaudited) | ||
| For the Year Ended | ||
| December 31, | ||
| 2014 | 2013 | |
| Net Revenue | $ 13,414,265 | $ 13,651,661 |
| Cost of Goods Sold | 5,280,909 | 6,943,043 |
| Gross Profit | 8,133,356 | 6,708,618 |
| Operating Costs and Expenses: | ||
| Selling and marketing | ||
| Commissions and consulting | 1,490,172 | 1,473,194 |
| Other selling and marketing expenses | 2,609,247 | 2,274,019 |
| 4,099,419 | 3,747,213 | |
| General and administrative | ||
| Salary and personnel costs | 2,327,482 | 2,351,953 |
| Professional fees and consulting costs | 1,667,788 | 1,744,250 |
| Other general and administrative expenses | 1,304,510 | 1,868,367 |
| 5,299,780 | 5,964,570 | |
| Total operating costs and expenses | 9,399,199 | 9,711,783 |
| Operating Loss | (1,265,843) | (3,003,165) |
| Other Income (Expense) | ||
| Loss on conversion of debt | — | (289,600) |
| Interest expense | (71,536) | (115,150) |
| Other | 25,220 | 278,658 |
| Total other income (expense) | (46,316) | (126,092) |
| Loss Before Income Taxes | (1,312,159) | (3,129,257) |
| Income Tax Expense | — | 96,033 |
| Net Loss | (1,312,159) | (3,225,290) |
| Net Loss Attributable to Non-Controlling Interest | (6,204) | (15,859) |
| Net Loss Attributable to Common Shareholders | $ (1,305,955) | $ (3,209,431) |
| Basic and Diluted Earnings per Share: | ||
| Weighted average common shares outstanding | 16,066,199 | 12,711,417 |
| Net Loss per share | $ (0.08) | $ (0.25) |
| Other Comprehensive Income: | ||
| Foreign currency translation adjustment | (14,893) | (13,167) |
| Comprehensive loss | $ (1,320,848) | $ (3,222,598) |
| DS Healthcare Group, Inc. (dba DS Laboratories) and Subsidiaries | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| (unaudited) | ||
| For the Year Ended | ||
| December 31, | ||
| 2014 | 2013 | |
| Cash Flows from Operating Activities: | ||
| Net Loss | $ (1,312,159) | $ (3,225,290) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 299,983 | 607,018 |
| Amortization of deferred issuance costs | — | 75,891 |
| Loss on sale of fixed assets | — | 21,637 |
| Impairment of intangible assets | 51,736 | 88,910 |
| (Recovery) provision for bad debts | (36,363) | 90,045 |
| (Recovery) provision for obsolete inventory | (162,463) | 49,720 |
| Stock issued for services | 681,459 | 717,981 |
| Loss on extinguishment of debt | — | 289,600 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 456,513 | (193,733) |
| Inventories | (1,119,486) | 701,651 |
| Prepaid expenses and other current assets | 11,170 | (206,612) |
| Accounts payable | (1,000,858) | (296,816) |
| Accrued expenses | 21,163 | 241,067 |
| Other current liabilities | 600,541 | 58,874 |
| Net cash used in operating activities | (1,508,764) | (980,057) |
| Cash Flows from Investing Activities: | ||
| Purchase of furniture and equipment | (130,079) | (46,794) |
| Purchase of injection molds | (5,750) | (35,139) |
| Proceeds from sale of fixed asset | 24,822 | — |
| Security deposits | (32,141) | (25) |
| Net cash used in investing activities | (143,148) | (81,958) |
| Cash Flows from Financing Activities: | ||
| Net (repayments) proceeds of credit facility | (582,383) | 133,725 |
| Proceeds of short term credit facility | 350,000 | — |
| Proceeds of shareholders' loans | — | 310,000 |
| Repayment of loans and notes | (11,429) | (117,752) |
| Repayments to related parties | — | 17,973 |
| Proceeds from sale of stock subscription | — | 10,000 |
| Proceeds from sale of common stock | 197,000 | 421,300 |
| Less issuance cost | (10,000) | (31,260) |
| Proceeds from private placement | — | 2,942,000 |
| Less issuance cost | — | (151,051) |
| Net cash (used) provided by financing activities | (56,812) | 3,534,935 |
| Effect of exchange rate changes on cash | (35,666) | (12,462) |
| (Decrease) Increase in Cash | (1,744,390) | 2,460,458 |
| Cash, Beginning of Period | 2,872,946 | 412,488 |
| Cash, End of Period | $ 1,128,556 | $ 2,872,946 |
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, salons and pharmacies. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.